Evidence map›Paper›PMID 39066267›Full record

ArticleViruses2024

Occurrence of Circulating Antibodies against the Hemagglutinins of Influenza Viruses in the 2022/2023 Epidemic Season in Poland.

Katarzyna Kondratiuk, Anna Poznańska, Karol Szymański, Emilia Czajkowska, Bartosz Mańkowski, Lidia B Brydak

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Katarzyna KondratiukLaboratory of Influenza Viruses and Respiratory Viruses, Department of Virology, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland.ORCID 0000-0002-0124-2971
Anna PoznańskaDepartment of Population Health Monitoring and Analysis, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland.
Karol SzymańskiLaboratory of Influenza Viruses and Respiratory Viruses, Department of Virology, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland.ORCID 0000-0003-3269-0774
Emilia CzajkowskaLaboratory of Influenza Viruses and Respiratory Viruses, Department of Virology, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland.ORCID 0009-0003-4116-8379
Bartosz MańkowskiLaboratory of Influenza Viruses and Respiratory Viruses, Department of Virology, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland.ORCID 0009-0002-4724-067X
Lidia B BrydakLaboratory of Influenza Viruses and Respiratory Viruses, Department of Virology, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland.

Funding

Ministry of Health (Poland) 6/8/85195/ NPZ/2021/1 094/827
6 · The paper itself

Abstract

The aim of this study was to determine the level of anti-hemagglutinin antibodies in blood sera collected from patients during the 2022/2023 epidemic season in Poland. A total of 700 sera samples from patients across the country were tested. The samples were divided into seven groups according to the age of the patients, with 100 samples from each age group. The hemagglutination inhibition test (OZHA) was used to determine the level of anti-hemagglutinin antibodies. The test results have confirmed the presence of anti-hemagglutinin antibodies for antigens A/Victoria/2570/2019 (H1N1)pdm09, A/Darwin/9/2021 (H3N2), B/Austria/1359417/2021 (B/Yamagata lineage) and B/ Phuket/3073/2013 (B/Victoria lineage) present in the influenza vaccine recommended by the World Health Organization (WHO) for the 2022/2023 epidemic season. The highest geometric mean antibody titres (GMT) and protection rate values (%) were recorded for hemagglutinin A/H3N2. In Poland, in the 2022/2023 epidemic season, the percentage of the population vaccinated against influenza was 5.7%. Therefore, the test results can be interpreted as the response of the immune system in patients who have been previously infected with an influenza virus.

Indexed as

Antibodies, ViralHemagglutination Inhibition TestsHemagglutinin Glycoproteins, Influenza VirusInfluenza A Virus, H3N2 SubtypeInfluenza, HumanAdolescentAdultAgedChildChild, PreschoolEpidemicsFemaleHumansInfantInfluenza A Virus, H1N1 SubtypeInfluenza B virusAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesantibodyGMThemagglutinin antibodiesinfluenzaprotection rateRNA virusesserum

Identifiers

PMID39066267
PMCPMC11281470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.